Enhancing regulatory T cells to improve treatment for myocarditis
Official title: Regulatory T cell augmentation by a long noncoding RNA: mechanisms and therapeutic applications in myocarditis
Funded at Cedars-Sinai Medical Center · NIH-10993144 · Data updated 2026-11-12
This study is looking at how a specific type of RNA can help boost special immune cells that reduce inflammation and help heal the heart in people with myocarditis, a heart condition often caused by viruses, with the hope of finding better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $417,500 |
| NIH project number | 5R01HL168296-02 |
| Project ID | NIH-10993144 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myocarditis, particularly those experiencing severe inflammation and related heart complications.
✕Less likely to help
Patients with chronic heart conditions unrelated to myocarditis or those who do not have an active inflammatory response may not benefit from this research.
What this research studies
This research investigates how a long noncoding RNA can enhance regulatory T cells, which play a crucial role in reducing inflammation and promoting healing in myocarditis, an inflammatory heart condition often triggered by viral infections. The approach focuses on understanding the mechanisms behind this enhancement and exploring its therapeutic applications. By potentially allowing for quicker and more effective treatments, this research aims to address the current lack of validated therapies for acute myocarditis. Patients may benefit from improved outcomes through enhanced immune responses that favor heart tissue repair.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves recovery and reduces complications for patients with myocarditis.
How similar studies have gone: Early phase clinical trials have shown promise in using autologous Treg cell infusion for various conditions, suggesting that similar approaches may be effective for myocarditis.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Marban, Eduardo — Cedars-Sinai Medical Center
- Study coordinator: Marban, Eduardo
Related research
Other NIH-funded projects on the same topics.
-
Rapid bedside molecular imaging of heart inflammation with ultrasound
A fast, point-of-care ultrasound test using special contrast bubbles may help doctors quickly see active heart inflammation in people with chest pain or suspected ACS.
-
Muscle-Related Enzyme TRIM55 and Autoimmune Heart Inflammation in Aicardi-Goutieres Syndrome
A new research project studies how a muscle-specific enzyme called TRIM55 drives autoimmune heart inflammation in a genetic syndrome.
-
Targeted CXCR3 blockade to treat immunotherapy-related heart inflammation
A targeted drug approach aims to prevent or lessen heart inflammation caused by immune therapies in cancer patients, using CXCR3-blocking strategies.
-
Viral tricks that disrupt heart cell connections in myocarditis
This grant looks at how a common cold virus (adenovirus) may mess with the heart’s electrical signals and could lead to dangerous arrhythmias in people with myocarditis.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Understanding how T cells and heart cells talk in a life-threatening heart inflammation from cancer immunotherapy
A doctor–scientist will study how immune T cells interact with heart cells in people treated for cancer who develop dangerous inflammation from immune checkpoint inhibitors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.